Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIM 23190

Drug Profile

BIM 23190

Alternative Names: BIM23190

Latest Information Update: 04 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomeasure Inc; Ipsen
  • Developer Ipsen
  • Class Antineoplastics; Oligopeptides; Piperazines
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 23 Jul 2003 BIM 23190 has been exclusively licensed to Teijin in Japan
  • 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 25 Sep 2002 Phase-II clinical trials in Diabetic retinopathy in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top